Literature DB >> 1722660

Selective usage of TCR V beta in tumor-specific CTL lines isolated from ovarian tumor-associated lymphocytes.

C G Ioannides1, R S Freedman.   

Abstract

We have developed a series of six CTL lines exhibiting preferential killing of autologous tumour cells from tumour-associated lymphocytes (TALs) infiltrating malignant ovarian ascites. Five out of six CTL lines showed increased percentages of V beta 8.1+ cells, four showed increased percentages of V beta 5.3+ cells and one showed increased percentages of V beta 6.7+ cells. On the contrary, fresh isolated TALs or autologous PBMCs, when stimulated by OKT3 mAb or other TAL cultures with nonspecific cytolytic function, did not show preferential usage of any of these families. Most important, V beta 8.1+ and V beta 6.7+ T cells within the CTL-TALs mediated cytoxicity against autologous targets. This represents the first demonstration of preferential usage of TCR V beta in ovarian tumor-specific CTLs and suggests possible association between tumor surveillance and TCR V beta genes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722660

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites.

Authors:  M Hishii; D Andrews; L A Boyle; J T Wong; F Pandolfi; P J van den Elsen; J T Kurnick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 2.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

Review 3.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

4.  Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.

Authors:  M Hishii; J T Kurnick; T Ramirez-Montagut; F Pandolfi
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

5.  Oligoclonality of CD8+ T cells in breast cancer patients.

Authors:  K Ito; J Fetten; H Khalili; S Hajdu; E Busch; R Pergolizzi; V Vinciguerra; M D Chang
Journal:  Mol Med       Date:  1997-12       Impact factor: 6.354

6.  Analysis of T cell receptor variability in fresh tumor-infiltrating lymphocytes from human head and neck cancer.

Authors:  K Chikamatsu; M Eura; K Nakano; Y Kanzaki; H Matsuoka; K Masuyama; T Ishikawa
Journal:  Jpn J Cancer Res       Date:  1994-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.